Swedish Orphan Biovitrum   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Stockholm Sweden (2010)
Status: Acquired by Advent International (2021)

Organization Overview

First Clinical Trial
2010
NCT00070616
First Marketed Drug
2010
palivizumab (Synagis)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Direttore Dipartimento di Malattie Infettive | Sobi | Sobi, Inc. | Sweden Orphan Biovitrum | Swedish Orphan Biovitrum | Swedish Orphan Biovitrum AB | Swedish Orphan Biovitrum AB (publ) | Swedish Orphan Biovitrum GmbH | Swedish Orphan Biovitrum (SOBI)

Active Ingredients

Marketed Drugs (5)

Key: Swedish Orphan Biovitrum (3) Acquired (2)

anakinra (Kineret) (2001)

emapalumab-lzsg (gamifant) (2018)

nitisinone (orfadin) (2016)

palifermin (Kepivance) (2004)

palivizumab (Synagis) (1998)

Drugs in Phase 4 Trials (4)

Key: Swedish Orphan Biovitrum (1) Acquired (3)

antihemophilic factor viii (Recombinant) (Adynovate) (2 trials)

avatrombopag (7 trials)

emapalumab-lzsg (gamifant) (11 trials)

palifermin (Kepivance) (14 trials)

Drugs in Phase 3 Trials (29)

Key: Swedish Orphan Biovitrum (11) Acquired (18)

anakinra (Kineret) (12 trials)

antihemophilic factor viii human (Hemofil M) (2 trials)

antihemophilic factor viii (Recombinant), Fc-fusion protein (Eloctate) (4 trials)

bile-salt-stimulated lipase (4 trials)

bivv001 (Advate) (1 trial)

carboplatin (paraplatin) (6 trials)

cisplatin (platinol) (2 trials)

coagulation factor ix (Recombinant) (Rixubis) (1 trial)

coagulation factor ix (Recombinant), Fc-fusion protein (Alprolix) (4 trials)

cyclophosphamide (cytoxan) (7 trials)

docetaxel (taxotere) (1 trial)

etoposide (vepesid) (2 trials)

fludarabine (fludara) (4 trials)

gemcitabine (gemzar) (4 trials)

human coagulation factor ix (Mononine) (1 trial)

ibritumomab tiuxetan (Zevalin) (3 trials)

ifosfamide (ifex) (1 trial)

immune globulin (human) (Gamastan) (1 trial)

mitoxantrone (novantrone) (1 trial)

nitisinone (orfadin) (5 trials)

oxaliplatin (eloxatin) (1 trial)

paclitaxel (taxol) (14 trials)

pacritinib (Vonjo) (28 trials)

pegcetacoplan (Empaveli) (2 trials)

pixuvri (12 trials)

prednisone (meticorten) (3 trials)

rituximab (rituxan) (10 trials)

vincristine (oncovin) (3 trials)

vinorelbine (navelbine) (2 trials)

Drugs in Phase 2 Trials (39)

Key: Swedish Orphan Biovitrum (8) Acquired (31)

allogeneic stem cells (2 trials)

arsenic trioxide (trisenox) (9 trials)

autologous hematopoietic stem cells (1 trial)

axicabtagene ciloleucel (Yescarta) (1 trial)

azacitidine (vidaza) (4 trials)

bendamustine (treanda) (1 trial)

brostallicin (1 trial)

busulfan (Myleran) (2 trials)

bvt.115959 (1 trial)

camptothecin (2 trials)

capecitabine (xeloda) (1 trial)

cetuximab (erbitux) (1 trial)

ct-2584 (1 trial)

cytarabine (cytosar-u) (2 trials)

decitabine (dacogen) (3 trials)

doxorubicin (Doxil) (2 trials)

fluorouracil (efudex) (1 trial)

leucovorin (1 trial)

leuprolide (lupron) (1 trial)

melphalan (alkeran) (1 trial)

naltrexone (revia) (2 trials)

ni-0101 (1 trial)

ni-0401 (2 trials)

ni-0801 (2 trials)

obinutuzumab (gazyva) (1 trial)

pemetrexed (alimta) (1 trial)

pracinostat (2 trials)

sirolimus (rapamune) (1 trial)

sobi-003 (2 trials)

sulfated oxysterol (2 trials)

symphoglobulin-d (1 trial)

tacrolimus (prograf) (1 trial)

temozolomide (temodar) (1 trial)

thalidomide (Thalomid) (1 trial)

thiotepa (1 trial)

tosedostat (3 trials)

triamcinolone (kenalog) (1 trial)

urea (2 trials)

vitamin c (1 trial)

Drugs in Phase 1 Trials (12)

Key: Swedish Orphan Biovitrum (2) Acquired (10)

clarithromycin (biaxin) (1 trial)

cp-870893 (1 trial)

cyanocobalamin (berocca) (1 trial)

daunorubicin (cerubidine) (1 trial)

heparin (liquaemin) (2 trials)

moxifloxacin (avelox) (1 trial)

ni-0701 (1 trial)

ni-1801 (1 trial)

rifampin (1 trial)

sb1578 (1 trial)

sobi002 (1 trial)

sodium chloride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis (Phase 2)

Arthritis, Gouty (Phase 2)

Arthritis, Juvenile (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Cystic Fibrosis (Phase 2)

Deglutition Disorders (Phase 2)

Ear Diseases (Phase 2)

Exocrine Pancreatic Insufficiency (Phase 2)

Fibrosis (Phase 2)

Graft vs Host Disease (Phase 2)

Head and Neck Neoplasms (Phase 3)

Hemophilia A (Phase 4)

Hemophilia B (Phase 3)

Infections (Phase 3)

Labyrinth Diseases (Phase 2)

Labyrinthitis (Phase 2)

Leukemia (Phase 1)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)

Leukemia, Lymphoid (Phase 1)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 4)

Lymphoma, B-Cell (Phase 2)

Lymphoma, Non-Hodgkin (Phase 4)

Mucocutaneous Lymph Node Syndrome (Phase 3)

Mucopolysaccharidoses (Phase 3)

Mucopolysaccharidosis III (Phase 3)

Mucositis (Phase 4)

Multiple Myeloma (Phase 4)

Myelodysplastic Syndromes (Phase 2)

Neoplasms (Phase 2)

Neoplasms, Plasma Cell (Phase 4)

Neuralgia (Phase 2)

Neurotoxicity Syndromes (Phase 2)

Premature Birth (Phase 3)

Purpura (Phase 2)

Purpura, Thrombocytopenic (Phase 2)

Purpura, Thrombocytopenic, Idiopathic (Phase 2)

Signs and Symptoms, Respiratory (Phase 3)

Stevens-Johnson Syndrome (Phase 2)

Still's Disease, Adult-Onset (Phase 3)

Stomatitis (Phase 3)

Tyrosinemias (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 155
  • # of Trial APIs: 84